US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Facebook and Instagram face European Union scrutiny over possible breaches of digital rulebook
LONDON (AP) — The European Union said Tuesday that it’s scrutinizing Facebook and Instagram over a r2024-05-01China endeavors to keep ancient city of Pingyao alive
Fixing a leaky roof is possibly an easy job for many people, but not for 51-year-old Hao Yongming wh2024-05-01FIS president hails China's skiing, snowboarding potential
International Ski and Snowboard Federation (FIS) president Johan Eliasch has spoken highly of the ra2024-05-01Coachella food prices SHOCK fans as festival
Coachella revelers have been left furious at the price of food as attendees share some of the eye-wa2024-05-01New Jersey seeks fourth round of offshore wind farm proposals as foes push back
LONG BEACH TOWNSHIP, N.J. (AP) — New Jersey is seeking a new round of proposals to build wind energy2024-05-01Apple CEO says that he wants to increase investments in Vietnam
HANOI, Vietnam (AP) — Apple CEO Tim Cook said Tuesday that he wants to further increase investment i2024-05-01
atest comment